MMJ eyes off $5 billion recreational market
The Canadian government recently announced the formation of a taskforce on marijuana legalisation and regulation – with an eye towards potentially legalising cannabis for recreational use.
The task force comprises of experts in law enforcement, medicine, policy, and health care administration – and is set to report back to the government by November this year.
The government has also committed to the introduction of a new regulatory system covering cannabis by the northern hemisphere spring next year.
If the task force recommends legalising cannabis for recreational use, MMJ told its shareholders that it would be in a unique position to take advantage of the market opportunity.
It recently gained approval to grow cannabis for medicinal uses in its Duncan facility in the country – becoming an authorised Licensed Producer under the Marihuana for Medical Purposes Regulations (MMPR).
It said that the requirements for consumer protection and product quality control in the potential new system could be quite similar to MMPR regulations.
There is no guarantee a new system will emerge from the taskforce, though, thus anyone looking at this stock to add to their portfolio should not use this as the basis for any investment decision and should apply caution to that decision.
The new government, led by Prime Minister Justin Trudeau, has affirmed its commitment to legalising cannabis for recreational use in the past – filling MMJ with a measure of confidence that changes will come to pass.
Currently, while growing cannabis for medical purposes is legal – it remains a Schedule II drug under the country’s Controlled Drugs and Substances Act.
Suffice to say, MMJ managing director Andreas Gideon is excited by the possibility of a new market opening up.
“The legalisation of the recreational market is expected to be a major value driver for MMJ and its shareholders, providing strategic access to an emerging market,” he said.
“As we have witnessed in states throughout North America, the legalisation of recreational marijuana has been a key catalyst in allowing regulated cultivators into a growing market.”
Located in Duncan, British Colombia, MMJ has invested approximately CAD$8 million ($A8.25 million) on the construction and establishment of the Duncan Facility, which contains high compliance items such as a Level 8 Narcotics Vault and a full service in-house biochemical and analytical laboratory.
Total area at the Duncan Facility is 10,000ft2.
MMJ is awaiting identical MMPR approval for its much larger Lucky Lake facility, which if approved could provide an 1100% increase in production capacity.
MMJ has two other wholly owned subsidiaries separate to United Greeneries, with Swiss based Satipharm which is already generating revenues from its CBD based medical products and Israeli based subsidiary PhytoTech Therapeutics involved in medical cannabis research.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.